<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01299142</url>
  </required_header>
  <id_info>
    <org_study_id>FGI-101-CP002</org_study_id>
    <secondary_id>W911NF-11-C-0029</secondary_id>
    <nct_id>NCT01299142</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics Study of Human Monoclonal Antibody (FGI-101-1A6)</brief_title>
  <official_title>Phase I Study of Human Monoclonal Antibody (FGI-101-1A6) in Normal Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Functional Genetics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Functional Genetics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of the anti-TSG101
      human monoclonal antibody (FGI-101-1A6)when administered intravenously to healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary -

      - To compare the safety profile of a single intravenous administration of FGI-101-1A6 as
      compared with Placebo

      Secondary

        -  To evaluate the pharmacokinetics (PK) of a singel intravenous administration of
           FGI-101-1A6

        -  To evaluate the immunogenicity of FGI-101-1A6
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessments</measure>
    <time_frame>60 days following infusion</time_frame>
    <description>Safety will be assessed by collecting data (physical exams, adverse event reporting, lab testing/analysis) and concomitant medications at each visit from pre-infusion period through post-infusion day 60, or the early withdrawal, if applicable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic analysis (PK)</measure>
    <time_frame>60 days following infusion</time_frame>
    <description>PK parameters will be determined for a single administration of FGI-101-1A6 as measured by an immunoassay for FGI-101-1A6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>From day 1 up to day 60 following infusion</time_frame>
    <description>Immunogenicity will be measured by testing serum on anti-FGI-101-1A6 generation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>FGI-101-1A6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug-FGI-101-1A6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention: Drug-Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FGI-101-1A6</intervention_name>
    <description>anti-TSG101 human monoclonal antibody, single dose</description>
    <arm_group_label>FGI-101-1A6</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers ages 18-45

          -  Normal laboratory (blood tests) results

        Exclusion Criteria:

          -  Prior immunization with live-attenuated vaccines
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Melinda Roberson</last_name>
    <phone>410-706-8877</phone>
    <email>mroberson@snbl-pc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SNBL Clinical Pharmacology Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberson</last_name>
      <email>mroberson@snbl-pc.com</email>
    </contact>
    <investigator>
      <last_name>Mohammed Al-Ibrahim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2011</study_first_submitted>
  <study_first_submitted_qc>February 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2011</study_first_posted>
  <last_update_submitted>February 16, 2011</last_update_submitted>
  <last_update_submitted_qc>February 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Michael Goldblatt, CEO</name_title>
    <organization>Functional Genetics</organization>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>antibodies</keyword>
  <keyword>monoclonal</keyword>
  <keyword>virus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

